Zydus Worldwide DMCC acquires Assertio

Zydus Worldwide DMCC has announced its acquisition of Assertio Holdings in an all-cash transaction valued at approximately $166.4 million. The deal highlights Zydus's efforts to expand its footprint in the pharmaceutical sector, particularly in markets targeting oncology treatments. This acquisition comes after a competitive bidding process, where Zydus defeated Garda Therapeutics, affirming its position through a superior offer that was primarily driven by offering favorable conditions for Assertio’s shareholders.

The definitive agreement stipulates that Zydus will purchase all outstanding shares of Assertio common stock for $23.50 per share. This offer represents a 30.6% premium over the prior $18.00 per share agreement with Garda Therapeutics and a 7.8% premium compared to a revised offer Garda had made earlier. The $23.50 price also constitutes a significant 75.8% premium over Assertio’s closing stock price as of March 20, 2026, the benchmark date set before discussions accelerated. Notably, the transaction will be executed through a tender offer followed by a second-step merger, both maintaining the same per-share compensation.

The strategic move by Zydus to acquire Assertio, a company with a strong focus on commercializing specialized oncology products, is seen as a way to bolster its product portfolio and enhance its positioning within the sector. Heather Mason, Chair of Assertio’s Board of Directors, indicated that the board viewed the Zydus proposal as superior after a comprehensive evaluation of the offer’s value and transaction certainty, added benefits being the lack of financing contingencies and no need for third-party financing.

For Assertio, the acquisition brings an end to its chapter as a standalone Nasdaq-listed entity, with its shares expected to cease trading upon completion of the deal in the second quarter of 2026. The acquisition does not require regulatory approval, simplifying the closing process. Assertio’s board has articulated confidence in the Zydus proposal, citing it as the best option after weighing several factors including execution risk and certainty of value.

The acquisition underscores the competitive nature of capital allocation in the pharmaceutical industry, where companies are aggressively pursuing growth through such transactions. While Zydus's acquisition strategy shows its commitment to expanding in segments like oncology, the deal sets a precedent for potential future consolidation within the sector, compelling other companies to reassess their strategic positions. The next milestone will be ensuring the completion of the tender offer, a pivotal step for Zydus as it seeks to solidify this strategic acquisition.